Clinical Manifestations and Diagnosis of Nonalcoholic Fatty Liver Disease

Overview

Journal Iran J Pathol

Date 2018 Mar 9

PMID 29515630

Citations 12

Authors

Mahmoodreza Khoonsari

Mohammadreza Mohammad Hosseini Azar

Ramak Ghavam

Khadijeh Hatami

Mosa Asobar

Ali Gholami

Abdolhalim Rajabi

Fahimeh Safarnezhad Tameshkel

Bahare Amirkalali

Masoudreza Sohrabi

Affiliations

Soon will be listed here.

Abstract

Background & Objective: Nonalcoholic fatty liver diseases (NAFLD) is the major cause of hepatocellular carcinoma and increases the risk of mortality. Understanding the trends of its clinical and biochemical changes is essential to identify patients with NAFLD that are at the greatest risk of nonalcoholic steatohepatitis (NASH) and cirrhosis in Iran.

Methods: Patients with NAFLD confirmed by ultrasonography were enrolled into the current study. They had negative serologic markers of viral or autoimmune hepatitis, no findings in favor of metabolic liver disease, and had not received medications that affect liver, such as silymarin and Ursobil. Biochemical and clinical symptoms and histological variables were evaluated for each patient. Descriptive statistics were used to compute all variables.

Results: A total of 206 patients, including 109 male and 97 female, with the mean age of 41.2 years were enrolled. The number of patients without obesity and diabetes were 34 (16.4%) and 48 (23.1%), respectively. Sleep disorder, delayed sleep, daytime sleepiness, and late dinner were noticeably common in patients with NAFLD. Furthermore, anxiety, thirst sensation, bloating, warming sensation, defecation disturbances, and upper abdominal pain were common among patients with NAFLD.

Conclusion: NAFLD is a heterogeneous disorder with vast clinical presentations. It seems that anxiety and gastrointestinal problem are common among such patients. Moreover, inadvertent sleep could have a considerable effect on developing NAFLD. Patients with diabetes have more severe NAFLD, based on clinical and histological findings.

Citing Articles

Carotenoids Improve Obesity and Fatty Liver Disease via Gut Microbiota: A Narrative Review.

Hashemi D, Fard M, Mohammadhasani K, Barati M, Nattagh-Eshtivani E Food Sci Nutr. 2025; 13(3):e70092.

PMID: 40071130 PMC: 11893484. DOI: 10.1002/fsn3.70092.

ACSS2 and metabolic diseases: from lipid metabolism to therapeutic target.

El-Kurjieh A, Al-Arab R, Hachem Q, Ibrahim J, Kobeissy P Lipids Health Dis. 2025; 24(1):74.

PMID: 40001058 PMC: 11853604. DOI: 10.1186/s12944-025-02491-z.

The correlation between metabolic dysfunction-associated steatotic liver disease (MASLD) grades and hemodynamic alterations of the portal, hepatic, and splenic vein and spleen size.

Borji S, Sani H, Ghorbani S, Soltani M, Mohammadi V, Elahi R J Ultrasound. 2024; .

PMID: 39537958 DOI: 10.1007/s40477-024-00965-x.

Polyphenols improve non-alcoholic fatty liver disease via gut microbiota: A comprehensive review.

Mohammadhasani K, Fard M, Mottaghi Moghaddam Shahri A, Khorasanchi Z Food Sci Nutr. 2024; 12(8):5341-5356.

PMID: 39139973 PMC: 11317728. DOI: 10.1002/fsn3.4178.

Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis.

Shea S, Lionis C, Kite C, Lagojda L, Uthman O, Dallaway A Front Endocrinol (Lausanne). 2024; 15:1357664.

PMID: 38689730 PMC: 11058984. DOI: 10.3389/fendo.2024.1357664.

References

Benotti P, Wood G, Argyropoulos G, Pack A, Keenan B, Gao X . The impact of obstructive sleep apnea on nonalcoholic fatty liver disease in patients with severe obesity. Obesity (Silver Spring). 2016; 24(4):871-7. PMC: 4936917. DOI: 10.1002/oby.21409. View

Motamed N, Zamani F, Rabiee B, Sima Saeedian F, Maadi M, Akhavan-Niaki H . The Best Obesity Indices to Use in a Single Factor Model Indicating Metabolic Syndrome: a Population Based Study. Arch Iran Med. 2016; 19(2):110-5. DOI: 0161902/AIM.008. View

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52. DOI: 10.1161/01.HYP.0000107251.49515.c2. View

Musso G, Gambino R, Cassader M, Pagano G . Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2010; 43(8):617-49. DOI: 10.3109/07853890.2010.518623. View

Petta S, Marrone O, Torres D, Buttacavoli M, Camma C, Di Marco V . Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2015; 10(12):e0142210. PMC: 4682677. DOI: 10.1371/journal.pone.0142210. View

Amirkalali B, Poustchi H, Keyvani H, Khansari M, Ajdarkosh H, Maadi M . Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran. Iran J Public Health. 2015; 43(9):1275-83. PMC: 4500430. View

Festi D, Schiumerini R, Marzi L, Di Biase A, Mandolesi D, Montrone L . Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Aliment Pharmacol Ther. 2013; 37(4):392-400. DOI: 10.1111/apt.12186. View

Alavian S, Mohammad-Alizadeh A, Esna-Ashari F, Ardalan G, Hajarizadeh B . Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int. 2008; 29(2):159-63. DOI: 10.1111/j.1478-3231.2008.01790.x. View

Bernsmeier C, Weisskopf D, Pflueger M, Mosimann J, Campana B, Terracciano L . Sleep Disruption and Daytime Sleepiness Correlating with Disease Severity and Insulin Resistance in Non-Alcoholic Fatty Liver Disease: A Comparison with Healthy Controls. PLoS One. 2015; 10(11):e0143293. PMC: 4648512. DOI: 10.1371/journal.pone.0143293. View

10.

Goh G, Pagadala M, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C . Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 2015; 3:141-5. PMC: 4661498. DOI: 10.1016/j.bbacli.2014.09.001. View

11.

Ashtari S, Pourhoseingholi M, Zali M . Non-alcohol fatty liver disease in Asia: Prevention and planning. World J Hepatol. 2015; 7(13):1788-96. PMC: 4491908. DOI: 10.4254/wjh.v7.i13.1788. View

12.

Sugimoto K, Takei Y . Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res. 2011; 41(10):911-20. DOI: 10.1111/j.1872-034X.2011.00867.x. View

13.

Wang Y, Zeng Y, Lin C, Chen Z . Hypertension and non-alcoholic fatty liver disease proven by transient elastography. Hepatol Res. 2016; 46(13):1304-1310. DOI: 10.1111/hepr.12688. View

14.

Newton J, Jones D, Henderson E, Kane L, Wilton K, Burt A . Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut. 2008; 57(6):807-13. DOI: 10.1136/gut.2007.139303. View

15.

Jakobsen M, Berentzen T, Sorensen T, Overvad K . Abdominal obesity and fatty liver. Epidemiol Rev. 2007; 29:77-87. DOI: 10.1093/epirev/mxm002. View

16.

Ekstedt M, Franzen L, Mathiesen U, Thorelius L, Holmqvist M, Bodemar G . Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44(4):865-73. DOI: 10.1002/hep.21327. View

17.

Younossi Z, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R . Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011; 53(6):1874-82. DOI: 10.1002/hep.24268. View

18.

Motamed N, Miresmail S, Rabiee B, Keyvani H, Farahani B, Maadi M . Optimal cutoff points for HOMA-IR and QUICKI in the diagnosis of metabolic syndrome and non-alcoholic fatty liver disease: A population based study. J Diabetes Complications. 2016; 30(2):269-74. DOI: 10.1016/j.jdiacomp.2015.11.019. View

19.

Williams C, Stengel J, Asike M, Torres D, Shaw J, Contreras M . Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2010; 140(1):124-31. DOI: 10.1053/j.gastro.2010.09.038. View

20.

McPherson S, Stewart S, Henderson E, Burt A, Day C . Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010; 59(9):1265-9. DOI: 10.1136/gut.2010.216077. View